the average final va ( 20/70 vs 20/100 ) , risk of developing neovascularization in ischemic tbrvo ( 3 % vs 34 % ) and risk of vitreous hemorrhage in proliferative tbrvo ( 10 % vs 57 % ) were all significantly better in treated eyes ( p less than or equal to 0.01 ) .
C0035328
tbrvo
C0015392
eyes